ZUBSOLV Drug Patent Profile

When do Zubsolv patents expire, and when can generic versions of Zubsolv launch?

Zubsolv is a drug marketed by Edenbridge Pharms and is included in one NDA. There are ten patents protecting this drug and four Paragraph IV challenges.

The generic ingredient in ZUBSOLV is buprenorphine hydrochloride; naloxone hydrochloride. Twenty-nine suppliers are listed for this compound. Additional details are available on the buprenorphine hydrochloride; naloxone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Zubsolv

A generic version of ZUBSOLV was approved as buprenorphine hydrochloride; naloxone hydrochloride by ACTAVIS ELIZABETH on February 22^nd, 2013.

Summary for ZUBSOLV

US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ZUBSOLV

Paragraph IV (Patent) Challenges for ZUBSOLV

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	0.7 mg/0.18 mg	204242	1	2017-05-04
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	2.9 mg/7.1 mg	204242	1	2015-12-21
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	8.6 mg/2.1 mg and 11.4 mg/2.9 mg	204242	1	2015-07-24
ZUBSOLV	Sublingual Tablets	buprenorphine hydrochloride; naloxone hydrochloride	1.4 mg/0.36 mg and 5.7 mg/1.4 mg	204242	1	2013-10-22

US Patents and Regulatory Information for ZUBSOLV

ZUBSOLV is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-003	Dec 11, 2014		RX	Yes	No			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-002	Jul 3, 2013		RX	Yes	No			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-004	Dec 11, 2014		RX	Yes	Yes			Y
Edenbridge Pharms	ZUBSOLV	buprenorphine hydrochloride; naloxone hydrochloride	TABLET;SUBLINGUAL	204242-002	Jul 3, 2013		RX	Yes	No			Y

International Patents for ZUBSOLV

When does loss-of-exclusivity occur for ZUBSOLV?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Cyprus

Denmark

European Patent Office

Japan

Poland

Portugal

Slovenia

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering ZUBSOLV around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2012311293
Australia	2013245546
Brazil	112014006356
Canada	2834327
Chile	2014000575
China	103813785

Supplementary Protection Certificates for ZUBSOLV

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2236132	CA 2015 00004	Denmark		PRODUCT NAME: ZOLPIDEM OG FARMACEUTISK ACCEPTABLE SALTE HERAF, HERUNDER ZOLPIDEMTARTRAT; NAT. REG. NO/DATE: 47607 OG 47608 20120719; FIRST REG. NO/DATE: (B BE424286 OG BE424295 20120718
2236132	122015000006	Germany		PRODUCT NAME: ZOLPIDEM UND PHARMAZEUTISCH VERTRAEGLICHE SALZE DAVON; NAT. REGISTRATION NO/DATE: 83439.00.00 83440.00.00 20120725 FIRST REGISTRATION: BELGIEN BE424286 BE424295 20120718
2236132	92636	Luxembourg		PRODUCT NAME: ZOLPIDEM ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES
2236132	300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NATIONAL REGISTRATION NO/DATE: RVG 108438 - 439 20160624; REGISTRATION NO/DATE: BE424286 20120718 BE424295 20120718
2236132	C300714	Netherlands		PRODUCT NAME: ZOLPIDEM EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN; NAT. REGISTRATION NO/DATE: RVG 108438 - 439 20130624; FIRST REGISTRATION: BE424286BE424295 2012180718
2236132	484	Finland

ZUBSOLV (buprenorphine/naloxone) Investment Scenario and Fundamentals Analysis: Patents, Exclusivity, Competition, and Revenue Outlook

Last updated: July 16, 2026

ZUBSOLV is a sublingual buprenorphine/naloxone product for opioid use disorder (OUD). The investment case hinges on (1) near-term formulary and share dynamics versus generic or authorized-competitor products, (2) regulatory and patent risk around listed Orange Book entries tied to the sublingual tablet/drug-product line, and (3) reimbursement trends for OUD maintenance and induction workflows. The core valuation drivers are earnings persistence in a mature category and the durability of product-specific regulatory exclusivity and patent estate rather than peak-growth upside.

What is ZUBSOLV and how does it generate revenue in opioid use disorder?

Market role. ZUBSOLV is a fixed-dose combination indicated for treatment of opioid dependence, used in induction and maintenance phases. Its go-to-market advantage historically centers on sublingual delivery attributes designed to improve dosing and tolerability versus earlier sublingual buprenorphine/naloxone presentations.

Pricing and reimbursement. OUD maintenance is generally reimbursed through commercial insurance, Medicaid, and Medicare Part D (availability varies by plan). Net price outcomes depend on pharmacy benefit design, prior authorization rules, step therapy, and manufacturer contracting. In mature OUD categories, share gains typically come from contracting and formulary inclusion rather than new clinical differentiation.

Utilization drivers.

• Patient retention in maintenance dosing
• Dose stability (avoidance of dose reductions due to tolerability issues)
• Induction conversion rates from other buprenorphine formulations
• Pharmacy channel shifts tied to PBM formularies

How strong is the patent estate for ZUBSOLV and what patents protect it?

Protection scope that matters for investment. For ZUBSOLV-like sublingual combination products, the economically relevant IP tends to fall into three buckets:

1. Composition and drug-product claims (buprenorphine/naloxone formulation and ratios)
2. Orally dissolving sublingual tablet/process claims (manufacturing and dissolution characteristics)
3. Method-of-use claims tied to OUD treatment regimens (if present)

Patent linkage mechanics. U.S. exclusivity and patent barriers typically show up via:

• Orange Book-listed patents for the drug product and formulation
• Exclusivity periods associated with NDA/BLA approvals or supplements

Investment implication. For a mature product, the probability-weighted risk is that one or more Paragraph IV challenges or non-IV generic/sponsor entries can pressure pricing quickly, with limited premium durability unless product differentiation is protected by enforceable patents.

What is the Orange Book status of ZUBSOLV and how many patents are listed?

Orange Book status determines launch timing. Orange Book “listed patents” and their expiration dates drive FDA approval eligibility for generics. The entry-risk framework for investors is:

• Which patents are listed for the relevant strength(s) and dosage form
• Which are still within enforceable periods
• Whether any patents are vulnerable via Paragraph IV certifications

Actionable diligence point. Analysts should map each listed patent to:

• Claim type (composition vs formulation vs method-of-use vs device)
• Jurisdiction (U.S. only for Orange Book listings)
• Status in litigation and any court-issued injunctions affecting the FDA approval clock

When does ZUBSOLV lose exclusivity and what expiration dates drive generic entry risk?

Exclusivity vs patent expiration. Even with patent coverage, investors must track two timing levers:

• Statutory or regulatory exclusivity (often tied to the NDA approval or supplement)
• Patent expiration dates for Orange Book-listed patents

Generic entry risk model.

• If key patents expire or are found invalid/not infringed, the FDA can approve a generic (or authorized product) before competing branded price erosion.
• If a Paragraph IV is pending and a court blocks approval or narrows design-work-arounds, generic timing shifts.

Investment implication. The market response to expiration is usually front-loaded in anticipation of entry, with contract renegotiations and channel stocking changes affecting realized pricing.

Which companies are challenging ZUBSOLV and what Paragraph IV litigation affects launch timing?

Paragraph IV is the central valuation variable for the post-branded period. In the U.S., the generic launch timeline is typically shaped by:

• Filing of ANDA with Paragraph IV certifications
• 30-month stay risk after notice of the Paragraph IV suit
• Court outcomes affecting whether FDA approval proceeds

What investors should anchor on.

• The identity of ANDA filers
• The specific Orange Book patents asserted and challenged
• Court docket outcomes (dismissal, settlement, consent judgments, infringement rulings)
• Whether settlements include “no-AG” agreements or market-sharing constraints (subject to antitrust oversight)

What patent litigation affects ZUBSOLV and how do settlement agreements change the forecast?

Settlement outcomes that matter.

• Authorized generic launch permissions
• Carve-outs by strength/dosage form
• Timing triggers linked to patent expiry
• Restrictions on labeling/labeling carve-outs that can slow generic substitution
• Payment terms and market protection structures that affect net pricing

Forecast sensitivity. Investment models for ZUBSOLV should treat litigation outcomes as scenario shocks:

• Upside: narrow injunction scope or delayed generic
• Base: controlled erosion with gradual substitution
• Downside: early resolution enabling faster entry and price compression

How does ZUBSOLV compare with Suboxone and other buprenorphine/naloxone sublingual products?

Competitor set.

• Suboxone (buprenorphine/naloxone sublingual film/tablet depending on formulation)
• Other buprenorphine/naloxone sublingual generics or authorized generics
• Adjunct OUD treatments that can shift patient flows (methadone, extended-release buprenorphine, naltrexone-based therapy)

Where ZUBSOLV competes.

• Induction and maintenance prescribing preferences
• Formulary positioning based on net pricing and rebates
• Patient adherence and tolerability perceptions that can affect switching

Commercial consequence for investors. In OUD, competition can come from both direct-buprenorphine product substitutes and indirect category switches if payer designs favor alternative delivery systems.

What formulations are protected by ZUBSOLV patents and what drug-product barriers exist?

Drug-product barriers. For sublingual combinations, formulation patents and manufacturing-process patents are often the main barriers because:

• Bioavailability depends on dissolution and sublingual absorption characteristics
• Manufacturing changes can alter critical quality attributes and dissolution profiles

Barrier assessment for market entry.

• Whether generics can design around dissolution/release profile claims
• Whether process claims limit allowable manufacturing
• Whether testing and comparability requirements slow scale-up

What generic entry risks exist for ZUBSOLV across strengths and dosing schedules?

Strength matters. OUD products are often marketed across multiple strengths. Generic entry risk differs by:

• Patent coverage mapped per strength (some claims may cover only certain strengths)
• Certification scope (which strengths are included in ANDA)
• Litigation strategy and carve-outs in settlement agreements

Manufacturing/IP execution risk.

• Bioequivalence and dissolution comparability requirements
• Changes to excipients and tablet characteristics that can trigger higher rejection rates or slower ramp

How does FDA regulatory status influence ZUBSOLV competition, substitution, and interchangeability?

Regulatory levers shaping competition.

• ANDA approvals and labeling sameness
• Whether generics are deemed therapeutically equivalent and substituted at the pharmacy level
• Any limitations tied to product-specific administration instructions

Substitution dynamics. Even after generic approval, utilization depends on:

• Pharmacy substitution laws and PBM edits
• Prescriber habits and prior authorization constraints
• Patient switching costs and tolerability experiences

What is the biosimilar risk for ZUBSOLV?

ZUBSOLV is a small-molecule drug combination. Biosimilar risk is not applicable.

Investment scenario: bull, base, and bear cases for ZUBSOLV fundamentals

Bull case (lower entry pressure and durable premium net pricing)

• Key Orange Book patents maintain enforceability through later expiration, limiting generic penetration.
• Litigation resolves in a way that delays approval or restricts substitution breadth.
• Contracting preserves share and net pricing; payer designs favor continued branded access.

Base case (generic/authorized entry gradually erodes pricing)

• A generic or authorized competitor enters, but share loss is gradual due to formulary constraints and prescriber inertia.
• ZUBSOLV maintains a meaningful installed base with incremental retention through tolerability and workflow fit.
• Net pricing declines but earnings durability holds through mix management and channel coverage.

Bear case (early resolution enables faster substitution and sharper price compression)

• One or more major patents are invalidated or design-arounds are cleared, enabling earlier-than-expected approvals across key strengths.
• Settlement terms permit earlier authorized generic or broaden entry scope.
• PBM and payer switches accelerate, causing abrupt net price erosion.

Commercial metrics investors should track for ZUBSOLV

Investment monitoring should focus on:

• Prescription counts and TRx trend by strength
• Share in OUD sublingual buprenorphine/naloxone class
• Average net price (ANP) trend, rebate intensity, and payer mix shift
• Inventory and channel fill indicators ahead of any generic catalyst
• Specialty pharmacy distribution changes and prior authorization frequency

Key decision points for R&D, licensing, or litigation strategy related to ZUBSOLV

Licensing.

• Evaluate whether authorized generics or product line extensions exist and whether they include margin-sharing or exclusivity designations.
• Screen for formulation-specific IP that could block improved versions (e.g., different dissolution characteristics).

R&D and lifecycle management.

• Map patent cliffs to candidate improvements in tablet architecture, dissolution kinetics, or stability profiles.
• Prioritize clinical and regulatory plans that can support new label claims if method-of-use or patient subgroup coverage is defensible.

Litigation posture.

• Focus on patents that appear in Orange Book for each strength and dosage form, with the most direct infringement pathways.
• Prioritize enforcement where injunction leverage can delay FDA approval and launch.

Geographic scope: where do patent and regulatory barriers matter most?

The investment thesis for generic substitution is primarily U.S.-driven because:

• Orange Book and ANDA frameworks govern approval and substitution in the U.S.
• Patent enforcement and Paragraph IV litigation are U.S.-centric for launch blocking.

Other jurisdictions affect long-run brand strategy, but U.S. exclusivity and litigation outcomes typically dominate near- to mid-term earnings.

---

Key Takeaways

• ZUBSOLV’s investment fundamentals are driven by U.S. exclusivity and the enforceability of Orange Book-listed patents tied to sublingual buprenorphine/naloxone drug-product/formulation coverage.
• The highest-risk catalyst is Paragraph IV litigation outcome and any settlement terms enabling earlier authorized generic or broader entry.
• Commercial resilience depends on payer contracting, net price maintenance, and patient retention within OUD maintenance workflows.
• The valuation swing factor is the timing and breadth of generic/authorized competitor substitution by strength, not generic entry in the aggregate.
• Investors should model bull/base/bear scenarios around the probability distribution of patent-validity outcomes and FDA approval timing for each strength.

---

FAQs

1. How do Orange Book patent expirations for sublingual buprenorphine/naloxone products translate into ANDA approval timing?
2. What settlement terms in Paragraph IV cases most often accelerate authorized generic competition for branded OUD drugs?
3. How does payer prior authorization for buprenorphine/naloxone affect TRx retention after generic entry?
4. What are the most common design-around strategies used to avoid infringement of sublingual tablet formulation or dissolution-related patents?
5. How do inventory and channel fill dynamics change around OUD product patent cliffs?

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. ANDA and Paragraph IV Certification Framework. U.S. Food and Drug Administration.
3. Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act) and related FDA regulations (21 U.S.C. § 355 and implementing regulations).